A study published in molecularbrain reports on the development of a novel peptide that, when delivered by nasal spray, prevents the SARS-CoV-2 spike protein from entering the lung and olfactory bulb cells of mice expressing human ACE2.
]. Briefly, HEK293T cells transiently transfected with hACE2 and TMPRSS2 were used as target cells, and HEK293T cells transiently transfected with SARS-CoV-2 S protein and GFP were used as effector cells. 40 h after transfection, target cells were treated with vehicle, TAT or peptide 15 min before adding the effector cells. The effector cells were detached from their culture dishes with 0.25% trypsin and overlaid onto a target cell monolayer at an effector:target cells ratio of 1:3.
Eight to ten week-old B6.Cg-Tg 2Prlmn/J mice were purchased from Jackson laboratories . Mice were housed in ventilated cages in a controlled environment that included standard enrichment. Animals were closely monitored for health and well-being daily by the investigator and supervised by a certified veterinarian in accordance with standard animal care guidelines by CACC . Animals were acclimatized to the environment for at least 7 days before experiments.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nanoparticle-Based Antimicrobial Fabrics Tested Against SARS-CoV-2In a new study, antimicrobial cotton fabrics based on silver (Ag), zinc oxide (ZnO), and Ag/ZnO nanoparticles were developed and tested against SARS-CoV-2.
Read more »
SARS-CoV-2 receptor-binding domain-based protein subunit vaccine shows promise against multiple SARS-CoV-2 variantsResearchers described a novel protein subunit vaccine comprising the receptor-binding domain (RBD) of ancestral SARS-CoV-2 spike (S) protein, dimerized with an immunoglobulin (Ig)G1-fraction, crystallizable (Fc) domain.
Read more »
A broad sarbecovirus-neutralizing antibody cocktailResearchers present a rational approach for identifying SARS-CoV-2 receptor-binding domain-targeted broad neutralizing antibody cocktails.
Read more »
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) - Cardiovascular DiabetologyBackground Fibrin(ogen) amyloid microclots and platelet hyperactivation previously reported as a novel finding in South African patients with the coronavirus 2019 disease (COVID-19) and Long COVID/Post-Acute Sequelae of COVID-19 (PASC), might form a suitable set of foci for the clinical treatment of the symptoms of Long COVID/PASC. A Long COVID/PASC Registry was subsequently established as an online platform where patients can report Long COVID/PASC symptoms and previous comorbidities. Methods In this study, we report on the comorbidities and persistent symptoms, using data obtained from 845 South African Long COVID/PASC patients. By using a previously published scoring system for fibrin amyloid microclots and platelet pathology, we also analysed blood samples from 80 patients, and report the presence of significant fibrin amyloid microclots and platelet pathology in all cases. Results Hypertension, high cholesterol levels (dyslipidaemia), cardiovascular disease and type 2 diabetes mellitus (T2DM) were found to be the most important comorbidities. The gender balance (70% female) and the most commonly reported Long COVID/PASC symptoms (fatigue, brain fog, loss of concentration and forgetfulness, shortness of breath, as well as joint and muscle pains) were comparable to those reported elsewhere. These findings confirmed that our sample was not atypical. Microclot and platelet pathologies were associated with Long COVID/PASC symptoms that persisted after the recovery from acute COVID-19. Conclusions Fibrin amyloid microclots that block capillaries and inhibit the transport of O2 to tissues, accompanied by platelet hyperactivation, provide a ready explanation for the symptoms of Long COVID/PASC. Removal and reversal of these underlying endotheliopathies provide an important treatment option that urgently warrants controlled clinical studies to determine efficacy in patients with a diversity of comorbidities impacting on SARS-CoV-2 infection and COVID-19 severity. We sug
Read more »
SARS-CoV-2 receptor-binding domain-based protein subunit vaccine shows promise against multiple SARS-CoV-2 variantsResearchers described a novel protein subunit vaccine comprising the receptor-binding domain (RBD) of ancestral SARS-CoV-2 spike (S) protein, dimerized with an immunoglobulin (Ig)G1-fraction, crystallizable (Fc) domain.
Read more »
A broad sarbecovirus-neutralizing antibody cocktailResearchers present a rational approach for identifying SARS-CoV-2 receptor-binding domain-targeted broad neutralizing antibody cocktails.
Read more »